期刊文献+

新型冠状病毒肺炎患者的治疗及不良反应监护 被引量:4

Treatment and Adverse Reaction Monitoring of Patients with COVID-19
原文传递
导出
摘要 目的探讨新型冠状病毒肺炎患者药物治疗与药物不良反应监护。方法隔离收治明确诊断的15例新型冠状病毒感染的肺炎患者,分轻型、普通型、重型及危重型,使用重组人干扰素α-2a、洛匹那韦/利托那韦片、盐酸阿比多尔片、磷酸氯喹、利巴韦林注射液等抗病毒药物治疗,联合抗病毒用药≤3种,同时进行对症支持治疗,在药物治疗过程中实施药学监护,及时发现药物不良反应并对症处理。结果截至2020年3月5日,治愈出院患者9例,在院患者6例,3例患者临床症状及胸部CT均好转,核酸检测为阳性,1例重型患者转为普通型,2例危重型患者转为重型;治疗过程中11例患者出现不同症状、不同程度的不良反应,不良反应发生率达73.33%,8例患者出现消化系统症状,2例患者出现皮疹伴瘙痒,1例患者治疗过程中肝酶轻微升高,根据国家不良反应监测中心分级,2例为新的不良反应,9例为一般的不良反应。结论目前没有经过临床验证有效的治疗方法治疗新型冠状病毒肺炎,在有限的诊疗方案推荐下需要摸索相关的药物治疗,包括药物选择、用法用量及疗程,药物在临床治疗时需进行不良反应监护,及时发现并对症处理,避免因药物引起的机体损害。 OBJECTIVE To explore the drug treatment and pharmaceutical care of patients with COVID-19. METHODS The 15 patients with COVID-19 were isolated and treated, who were divided into mild type, normal type, severe type and critical type. Antiviral drugs such as recombinant human interferon α-2 a, lopinavir/ritonavir tablets, abidol hydrochloride tablets, chloroquine phosphate and ribavirin injection were used, and no more than 3 kinds of antiviral drugs were used. Pharmaceutical care was carried out in the course of drug treatment. Monitor the adverse reactions during treatment and give symptomatic treatment in time. RESULTS By March 5, 2020, 9 patients were cured, 6 patients were treated in hospital, 3 patients’ clinical symptoms and CT were improved, but nucleic acid test was positive, 1 severe patient turned to normal type, 2 critically ill patients changed to severe type. During the treatment, 11 patients had different symptoms and degrees of adverse reactions, the incidence of adverse reactions was 73.33%, 8 patients had digestive system symptoms, 2 patients developed rash with pruritus, 1 patient slightly increased liver enzymes during treatment. According to the classification of the National Adverse Reaction Monitoring Center, 2 cases were new adverse reactions and 9 cases were general adverse reactions. CONCLUSION At present, there is no clinically proven effective treatment for novel coronaviru. Under the limited recommendations of treatment, it is necessary to explore the relevant drug treatment, including drug selection, drug usage and dosage, and drug treatment course. At the same time, adverse reaction monitoring, timely detection and symptomatic treatment are needed to avoid damage caused by drugs.
作者 王琳 王静 涂杰霞 司果 姜琪 任雪松 杨英 柯英 蒋正方 WANG Lin;WANG Jing;TU Jiexia;SI Guo;JIANG Qi;REN Xuesong;YANG Ying;KE Ying;JIANG Zhengfang(Department of Pharmacy,Sichuan Mianyang 404 Hospital,Mianyang 621000,China;Department of Infectious Diseases,Sichuan Mianyang 404 Hospital,Mianyang 621000,China;Department of Respiratory Medicine,Sichuan Mianyang 404 Hospital,Mianyang 621000,China;Department of Neurosurgery,Sichuan Mianyang 404 Hospital,Mianyang 621000,China)
出处 《中国现代应用药学》 CAS CSCD 北大核心 2020年第5期530-535,共6页 Chinese Journal of Modern Applied Pharmacy
基金 四川省基层卫生事业发展中心项目(SWFZ19-Y-40) 绵阳市科技局应急科研项目(2020YJKY013)。
关键词 新型冠状病毒肺炎 药物治疗 不良反应监护 COVID-19 drug therapy adverse reactions monitoring
  • 相关文献

参考文献5

二级参考文献40

共引文献127

同被引文献47

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部